T Regulatory cells (Tregs) act as a double-edged sword by regulating immune homeostasis
(protective role) and inhibiting immune responses in different disease settings (pathological …

The quest for treatment-free remission (TFR) and deep molecular response (DMR) in
chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors …

Daratumumab targets CD38-expressing myeloma cells through a variety of immune-
mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent cell …

Here we show that overexpression or activation of B-cell maturation antigen (BCMA) by its
ligand, a proliferation-inducing ligand (APRIL), promotes human multiple myeloma (MM) …

Background Multiple myeloma is an incurable plasma cell malignancy that is mostly
restricted to the bone marrow. Cancer-induced dysfunction of cytotoxic T cells at the tumor …

Harnessing the power of the immune system to recognize and eliminate cancer cells is a
longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune …

Remarkable progress has been achieved in multiple myeloma, and patient median survival
has been extended 3-to 4-fold. Specifically, there have been 18 newly approved treatments …

Abstract Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune
evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody …

Inducing effective anti-tumor immunity has become a major therapeutic strategy against
cancer. Dendritic cells (DC) are a heterogenous population of antigen presenting cells that …

Enhancing natural killer (NK) cell cytotoxicity by blocking inhibitory signaling could lead to
improved NK-based cancer immunotherapy. Thus, we have developed a highly efficient …